脂肪生成
脂肪变性
脂肪肝
肝X受体
非酒精性脂肪肝
HMGB1
生物
脂毒性
转录因子
核受体
脂质代谢
内分泌学
癌症研究
内科学
医学
受体
基因
遗传学
疾病
胰岛素抵抗
胰岛素
作者
Jean Personnaz,Enzo Piccolo,Alizée Dortignac,Jason S. Iacovoni,Jérôme Mariette,Vincent Rocher,Arnaud Polizzi,Aurélie Batut,Simon Deleruyelle,Lucas Bourdens,Océane Delos,Lucie Combes‐Soia,Romain Paccoud,Elsa Moreau,Frédéric Martins,Thomas Clouaire,Fadila Benhamed,Alexandra Montagner,Walter Wahli,Robert F. Schwabe
出处
期刊:Science Advances
[American Association for the Advancement of Science]
日期:2022-03-25
卷期号:8 (12): eabg9055-eabg9055
被引量:18
标识
DOI:10.1126/sciadv.abg9055
摘要
Dysregulations of lipid metabolism in the liver may trigger steatosis progression, leading to potentially severe clinical consequences such as nonalcoholic fatty liver diseases (NAFLDs). Molecular mechanisms underlying liver lipogenesis are very complex and fine-tuned by chromatin dynamics and multiple key transcription factors. Here, we demonstrate that the nuclear factor HMGB1 acts as a strong repressor of liver lipogenesis. Mice with liver-specific Hmgb1 deficiency display exacerbated liver steatosis, while Hmgb1-overexpressing mice exhibited a protection from fatty liver progression when subjected to nutritional stress. Global transcriptome and functional analysis revealed that the deletion of Hmgb1 gene enhances LXRα and PPARγ activity. HMGB1 repression is not mediated through nucleosome landscape reorganization but rather via a preferential DNA occupation in a region carrying genes regulated by LXRα and PPARγ. Together, these findings suggest that hepatocellular HMGB1 protects from liver steatosis development. HMGB1 may constitute a new attractive option to therapeutically target the LXRα-PPARγ axis during NAFLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI